Taymur Ibrahim, Özdel Kadir, Özen Nurper Erberk, Güngör Buket Belkiz, Atmaca Murad
Department of Psychiatry, Şevket Yilmaz Teaching and Research Hospital, Bursa, Turkey.
Psychiatr Danub. 2015 Mar;27(1):25-30.
A close relationship has been shown between mood disorders and pteridine levels. The aim of this study was to examine alterations in the urine neopterine levels of patients with major depressive disorder (MDD) who responded to paroxetine during the initial treatment and to compare their levels to those of healthy controls.
Sixteen patients with major depression and 19 healthy controls were enrolled in the study. In order to assess depression severity levels, the Beck Depression Inventory, the Beck Anxiety Inventory, and the State-Trait Anxiety Inventory were administered. Urinary neopterine values that were measured using high pressure liquid chromatography (HPLC) were compared using non-parametric tests for the MDD patients before and after treatment. Urine neopterine levels in MDD patients before and after treatment were compared to those of the healthy control group.
Urinary neopterine levels were recorded as follows: For the MDD group before treatment the mean level was 187.92±54.79 μmol/creatinine. The same group under treatment at 4 to 8 weeks was at 188.53±4962 μmol/creatinine, and the healthy control group showed 150.57±152.98 μmol/creatinine levels. There was no statistically significant difference in the urinary neopterine levels among the MDD patients before and after treatment (p=0.938). When urine neopterine levels in MDD patients before and after treatment were compared to those of the healthy control group, levels in the MDD group were found to be significantly higher (p=0.004 and p=0.005, respectively).
Findings from the current study suggest that despite treatment response, depression is related to higher levels of urine neopterine. Paroxetine treatment has no significant effect on urine levels of neopterine in MDD patients.
情绪障碍与蝶啶水平之间已显示出密切关系。本研究的目的是检查在初始治疗期间对帕罗西汀有反应的重度抑郁症（MDD）患者尿液新蝶呤水平的变化，并将其水平与健康对照者的水平进行比较。
16例重度抑郁症患者和19名健康对照者纳入本研究。为了评估抑郁严重程度，使用了贝克抑郁量表、贝克焦虑量表和状态-特质焦虑量表。使用非参数检验比较MDD患者治疗前后通过高压液相色谱（HPLC）测量的尿新蝶呤值。将MDD患者治疗前后的尿新蝶呤水平与健康对照组进行比较。
尿新蝶呤水平记录如下：MDD组治疗前平均水平为187.92±54.79μmol/肌酐。该组在4至8周治疗时为188.53±4962μmol/肌酐，健康对照组显示为150.57±152.98μmol/肌酐水平。MDD患者治疗前后尿新蝶呤水平无统计学显著差异（p = 0.938）。当将MDD患者治疗前后的尿新蝶呤水平与健康对照组进行比较时，发现MDD组的水平显著更高（分别为p = 0.004和p = 0.005）。
本研究结果表明，尽管有治疗反应，但抑郁症与较高的尿新蝶呤水平有关。帕罗西汀治疗对MDD患者的尿新蝶呤水平无显著影响。
